| General Information | |
|---|---|
| ZINC ID | ZINC000049035100 |
| Molecular Weight (Da) | 434 |
| SMILES | CC1(C)C[C@H](N)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2O1 |
| Molecular Formula | C22Cl3N2O1 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 115.088 |
| HBA | 2 |
| HBD | 0 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 28 |
| LogP | 6.261 |
| Activity (Ki) in nM | 7762.471 |
| Polar Surface Area (PSA) | 48.14 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | + |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | 0 |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.82612597 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.23 |
| Ilogp | 3.87 |
| Xlogp3 | 5.97 |
| Wlogp | 6.61 |
| Mlogp | 4.91 |
| Silicos-it log p | 6.58 |
| Consensus log p | 5.59 |
| Esol log s | -6.63 |
| Esol solubility (mg/ml) | 0.000101 |
| Esol solubility (mol/l) | 0.00000023 |
| Esol class | Poorly sol |
| Ali log s | -6.76 |
| Ali solubility (mg/ml) | 0.0000759 |
| Ali solubility (mol/l) | 0.00000017 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.54 |
| Silicos-it solubility (mg/ml) | 0.00000012 |
| Silicos-it solubility (mol/l) | 2.87E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.71 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.83 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.418 |
| Logd | 4.437 |
| Logp | 6.79 |
| F (20%) | 0.003 |
| F (30%) | 0.004 |
| Mdck | 7.50E-06 |
| Ppb | 1.0031 |
| Vdss | 1.7 |
| Fu | 0.01 |
| Cyp1a2-inh | 0.76 |
| Cyp1a2-sub | 0.862 |
| Cyp2c19-inh | 0.673 |
| Cyp2c19-sub | 0.083 |
| Cl | 6.892 |
| T12 | 0.024 |
| H-ht | 0.683 |
| Dili | 0.926 |
| Roa | 0.246 |
| Fdamdd | 0.917 |
| Skinsen | 0.025 |
| Ec | 0.003 |
| Ei | 0.01 |
| Respiratory | 0.373 |
| Bcf | 4.368 |
| Igc50 | 5.236 |
| Lc50 | 7.523 |
| Lc50dm | 6.762 |
| Nr-ar | 0.26 |
| Nr-ar-lbd | 0.495 |
| Nr-ahr | 0.644 |
| Nr-aromatase | 0.823 |
| Nr-er | 0.631 |
| Nr-er-lbd | 0.75 |
| Nr-ppar-gamma | 0.068 |
| Sr-are | 0.824 |
| Sr-atad5 | 0.12 |
| Sr-hse | 0.142 |
| Sr-mmp | 0.91 |
| Sr-p53 | 0.936 |
| Vol | 407.531 |
| Dense | 1.06 |
| Flex | 0.087 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 0 |
| Qed | 0.476 |
| Synth | 3.087 |
| Fsp3 | 0.227 |
| Mce-18 | 80.556 |
| Natural product-likeness | -0.13 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Accepted |